EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Terminal Differentiation ◽

Human Squamous Cell Carcinoma

Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction

Tumor Biology ◽

10.1007/s13277-014-2932-7 ◽

2014 ◽

Vol 36 (4) ◽

pp. 2993-2999 ◽

Cited By ~ 3

Author(s):

Lixia Zhang ◽

Xiaokun Yang ◽

Bei Zhao ◽

Zhen Cai

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Acquired Resistance ◽

Egfr Tyrosine Kinase

Squamous cell carcinoma transformation of lung adenocarcinoma after tyrosine kinase inhibitor therapy: Cytological approach

Cytopathology ◽

10.1111/cyt.12813 ◽

2020 ◽

Vol 31 (3) ◽

pp. 232-235 ◽

Cited By ~ 1

Author(s):

Alexandra Grosse ◽

Claudia Grosse

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Lung Adenocarcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Inhibitor Therapy ◽

Tyrosine Kinase Inhibitor Therapy

Deguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma

International Journal of Molecular Sciences ◽

10.3390/ijms18020262 ◽

2017 ◽

Vol 18 (2) ◽

pp. 262 ◽

Cited By ~ 4

Author(s):

Yuh Baba ◽

Toyonobu Maeda ◽

Atsuko Suzuki ◽

Satoshi Takada ◽

Masato Fujii ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Neck Squamous Cell Carcinoma ◽

Apoptotic Activity

Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor

Journal of Clinical Pathology ◽

10.1136/jclinpath-2015-202866 ◽

2015 ◽

Vol 68 (4) ◽

pp. 320-321 ◽

Cited By ~ 26

Author(s):

Justine L Kuiper ◽

Merle I Ronden ◽

Annemarie Becker ◽

Daniëlle A M Heideman ◽

Peter van Hengel ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Nsclc Patient ◽

Egfr Tyrosine Kinase ◽

Egfr Mutated

A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.4083 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 4083-4083

Author(s):

Hyo Song Kim ◽

Han Sang Kim ◽

Jong-Mu Sun ◽

Myung-Ju Ahn ◽

Keunchil Park ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Egf Receptor ◽

Kinase Inhibitor ◽

Metastatic Squamous Cell Carcinoma ◽

Carcinoma Of Esophagus

Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model

Head & Neck ◽

10.1002/hed.21455 ◽

2010 ◽

pp. n/a-n/a ◽

Cited By ~ 5

Author(s):

Daisuke Sano ◽

David R. Fooshee ◽

Mei Zhao ◽

Genevieve A. Andrews ◽

Mitchell J. Frederick ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Mouse Model ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Molecular Therapy ◽

Targeted Molecular Therapy

Efficacy and Toxicity of Tyrosine Kinase Inhibitor Along with Platinum Based Concurrent Chemoirradiation In Locally Advanced Squamous Cell Carcinoma of Head And Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2010.07.271 ◽

2010 ◽

Vol 78 (3) ◽

pp. S105 ◽

Cited By ~ 1

Author(s):

P.K. Nandwani ◽

R. Vyas ◽

M. Mehta ◽

J. Neema

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma

Abstract CT229: A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor, dacomitinib, in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN)

10.1158/1538-7445.am2014-ct229 ◽

2014 ◽

Author(s):

Han Sang Kim ◽

Hyung Joo Kwon ◽

Myung-Ju Ahn ◽

Byung Woog Kang ◽

Jong-Mu Sun ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Metastatic Squamous Cell Carcinoma

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Egf Receptor ◽

Kinase Inhibitor ◽

Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5505 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5505-5505 ◽

Cited By ~ 13

Author(s):

K. J. Harrington ◽

A. Berrier ◽

M. Robinson ◽

E. Remenar ◽

M. Housset ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Phase Ii Study ◽

Locally Advanced

EGFR Tyrosine Kinase Inhibitor Pelitinib Regulates Radiation-Induced p65-Dependent Telomerase Activation in Squamous Cell Carcinoma

Radiation Research ◽

10.1667/rr3028.1 ◽

2013 ◽

Vol 179 (3) ◽

pp. 304-312 ◽

Cited By ~ 5

Author(s):

Natarajan Aravindan ◽

Sheeja Aravindan ◽

Terence S. Herman ◽

Mohan Natarajan

Keyword(s):

Squamous Cell Carcinoma ◽

Tyrosine Kinase ◽

Cell Carcinoma ◽

Squamous Cell ◽

Kinase Inhibitor ◽

Egfr Tyrosine Kinase ◽

Radiation Induced